The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 124, Issue 9, 2017, Pages 1394-1401

  Munro, A ^a   Gillespie, C ^a   Cotton, S ^a   Busby Earle, C ^b   Kavanagh, K ^c   Cuschieri, K ^d   Cubie, H ^d   Robertson, C ^c   Smart, L ^b   Pollock, K ^e   Moore, C ^d   Palmer, T ^f   Cruickshank, M E ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NHS LOTHIAN   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d Scottish Human Papillomavirus Reference Laboratory   (United Kingdom)

^e HEALTH PROTECTION SCOTLAND   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cervical intraepithelial neoplasia; cervical screening; colposcopy; human papillomavirus; human papillomavirus genotyping; human papillomavirus vaccine

Indexed keywords

MESSENGER RNA; VIRUS DNA; WART VIRUS VACCINE;

ADULT; ARTICLE; COLPOSCOPY; CONTROLLED STUDY; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN TISSUE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; SCOTLAND; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS; CLINICAL TRIAL; COMPLICATION; CROSS-SECTIONAL STUDY; DIAGNOSTIC IMAGING; GENETICS; ISOLATION AND PURIFICATION; MULTICENTER STUDY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SCOTLAND; UTERINE CERVICAL NEOPLASMS;

EID: 85014771895     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.14563     Document Type: Article

References (23)

1. Cuschieri K, Brewster DH, Williams ARW, Millan D, Murray G, Nicoll S, et al. Distribution of HPV types associated with cervical cancers in scotland and implications for the impact of HPV vaccines. Br J Cancer 2010;102:930–2.
2. Information Services Division. HPV immunisation uptake rates: School year 2011/12. [http://www.isdscotland.org/Health-Topics/Child-Health/Publications/2012-09-25/2012-09-25-HPV-Uptake-Report.pdf?85877627135]. Updated 25 September 2012. Accessed 13 December 2012.
3. Kavanagh K, Pollock K, Potts A, Love J, Cuschieri K, Cubie H, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. BJC 2014;110:2804–11.
4. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004;364:249–56.
5. Chase DM, Kalouyan M, DiSaia PJ. Colposcopy to evaluate abnormal cervical cytology in 2008. Am J Obstet Gynaecol 2009;200:472–80.
6. Jeronimo J, Massad LS, Schiffman M. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynaecol 2007;197:47.e1–47.e8.
7. Louwers JA, Zaal A, Kocken M, Ter Harmsel W, Graziosi G, Spruijt J, et al. Dynamic spectral imaging colposcopy: higher sensitivity for detection of premalignant cervical lesions. BJOG 2010;118:309–18.
8. Zaal A, Louwers JA, Berkhof J, Kocken M, Ter Harmsel WA, Graziosi GC, et al. Agreement between colposcopic impression and histological diagnosis among human papillomavirus type 16-positive women: a clinical trial using dynamic spectral imaging colposcopy. BJOG 2012;119:537–44.
9. van der Marel j, van Baaers R, Quint W. The impact of human papillomavirus genotype on colposcopic appearance: a cross-sectional analysis. BJOG 2014;121:1117–26.
10. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013;309:1793–802.
11. ® Media MDx Handbook. Manchester, UK: QIAGEN Ltd., 2010.
12. Roche Molecular Systems I, ed. LINEAR ARRAY HPV Genotyping Test. Doc Rev. 9.0 ed. Mannheim, Germany: Roche Diagnostics GmbH, 2012.
13. International Agency for Research on Cancer. Biological agents. IARC Monographs on the evaluation of carcinogenic risks to humans. 2012;100B.
14. NorChip, ed. PreTect HPV Proofer User Guide. Version 2.0 ed. Klokkarstua, Norway: NorChip AS, 2011.
15. Information Services Division Scotland. Scottish cervical screening programme annual uptake data. [http://www.isdscotland.org/Health-Topics/Cancer/Cervical-Screening/] Updated 2015. Accessed 20 May 2016.
16. Brotherton JML, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in victoria, australia: an ecological study. Lancet 2011;377:2085–92.
17. Kelly RS, Walker P, Kitchener H, Moss SM. Incidence of CIN grade 2 or worse in colposcopy-negative women with low grade cytological abnormalities. BJOG 2011;1471:20–24.
18. Barut MU, Kale A, Bozkurt M, Agacayak E, Ozekinci S, Gul T. Analysis of sensitivity, specificity, and positive and negative predictive values of smear and colposcopy in diagnosis of premalignant and malignant cervical lesions. Med Sci Monit 2015;21:3860–7.
19. Brenner HGO. Variation of sensitivity, specificificity, likelihood ratios and predictive values with disease prevalence. Stat Med 1997;16:981–91.
20. Pollock K, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in scotland. BJC 2014;111:1824–30.
21. La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W. HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine 2007;25:8352–8.
22. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890–907.
23. Cameron R, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009–2013. EID 2016;22:56–64.